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Abstract 
The purpose of this study was to examine the relationship between physical activity (PA) and 
the APOE-4 on cognitive functioning in cognitively normal older adults. Two hundred participants 
(mean age = 64.35 years old, male N = 61, female N = 139) estimated their average PA, underwent 
genetic testing, and completed a battery of neurocognitive tests assessing executive functioning, 
long-term memory, learning, and working memory. A cross-sectional between subjects 2 (APOE-4 
carrier status: carrier, non-carrier) x 2 (Physical activity: low, high) ANCOVA (age as covariate) was 
run for each cognitive test. Results revealed no significant main effects or significant interactions 
between PA and APOE-4 carrier status across any cognitive domains. These results were contrary 
to the hypotheses. It was concluded that the protective effect of PA, and the risk effect of APOE-4 
that is present in cases of dementia may not have an effect on non-pathological cognitive decline. 
Future large-scale research is required to determine whether this is a true effect, or due to 
methodological limitations. Future research may benefit from the use of an objective measure of PA, 
inclusion of a measure of global cognitive functioning, and the use of a PA intervention or 
longitudinal design. 
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 Cognitive decline is a natural part of the ageing process (Deary et al., 2009). Previous 
literature has identified potential risk factors and protective factors of both pathological and non-
pathological cognitive functioning. These factors can be environmental or genetic. The most 
researched environmental protective factor is physical activity (PA), and the most researched genetic 
risk factor is presence of the Apolipoprotein E 4 allele (Cedazo-Minguez, 2007; Sofi et al., 2010).  
There is a lack of consistency in research regarding the gene environment interaction of cognitive 
decline (Luck et al., 2014).   Further, previous literature has assessed global cognition rather than 
domain specific cognition (Rovio et al., 2005, Yang et al., 2014). Thus, the aim of this paper is to 
provide insight on the interaction between low and high PA on carriers and non-carriers of APOE-4 
on four domains of cognitive functioning; executive functioning (EF), long-term memory (LTM), 
learning, and working memory (WM).  
Cognitive Decline and Ageing 
Age-associated cognitive decline generally begins in early adulthood, with noticeable deficits 
typically occurring from late mid-life onwards (50-60 years old; Salthouse, 2009). The United 
Nations (2015) predict that by 2050, the number of people aged over 60 years old will have tripled 
globally since 2000. Thus, as life expectancy increases and the human population continues to age, 
the prevalence of age-associated cognitive decline (non-pathological cognitive decline) and 
neurodegenerative dementias (pathological cognitive decline) continues to increase (Brown et al., 
2017; Murman, 2015). In 2016 in Australia, the annual cost of cognitive decline including dementias 
equated to $14.25 billion (such as cost of hospitalisation, pharmaceuticals, and GP visits; Brown, 
Hansnata, & Anh La, 2017). These figures demonstrate that age-associated cognitive decline is an 
immediate ever-growing problem. Brayne et al. (2007, p.233) state that due to the non-pathological 
nature of age-associated cognitive decline it is largely ignored, so much so that he referred to it as 
‘the elephant in the room’.  
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Despite the growing prevalence and cost of cognitive decline, there is a lack of research 
regarding intervention, diagnosis, treatment, protective factors, and established causal risk factors of 
cognitive decline (Luck et al., 2014). Before examining the relationship between risk factors, 
protective factors, and cognitive decline, it is important to identify the facets of cognition that are 
most affected by ageing. In doing so, the identification of effective domain-specific prevention 
strategies can be derived.  
Cognitive Processes and Ageing 
 According to Murman (2015), cognitive abilities can be divided into those that are 
more prone to age-related decline (fluid abilities) and those that remain somewhat unaffected 
(crystallised abilities). Fluid abilities include the effective manipulation and transformation of 
information that require complex cognitive processing at the time of assessment. Fluid abilities 
include EF and WM. Executive functions are a set of cognitive process that encompass the ability to 
self-regulate behaviour and achieve goals (Salthouse, Atkinson, & Berish, 2003). These processes 
involve inhibition, visual and verbal attention, task-switching, and cognitive flexibility (Salthouse et 
al., 2003). Working memory is a fluid ability that refers to the capacity to temporarily hold and 
manipulate information (Coles & Tomporowski, 2008; Salthouse, 2010). 
Conversely, crystallised abilities include knowledge and memories that have accumulated 
over time, such as general knowledge, semantic memory, and vocabulary. This includes LTM and 
learning. Long-term memory is a crystallised ability that involves the consolidation and retrieval of 
information that occurred in the past (Salthouse, 2010). These memories can be consciously 
available, such as the ability to recall facts, or procedural, such has how to write, walk, and drive 
(Coles & Tomporowski, 2008). Learning refers to the process of either acquiring new information or 
modifying existing information (Coles & Tomporowski, 2008).  
Cross-sectional research suggests that crystallised abilities increase up and into adulthood, 
only beginning to decrease in late adulthood (approximately 80 years old). Conversely, fluid abilities 
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begin to decline in mid-adulthood and the pace of decline increases as age increases (Deary et al., 
2009; Harada, Natelson Love, & Triebel, 2013). Whilst previous literature has identified declines in 
general cognitive ability, the differential determinants of cognitive decline in individuals are not fully 
understood (Etiner et al., 2015). It has been suggested that lifestyle factors and genetic factors may 
protect against, or increase risk of cognitive decline in older adults (Lindsay et al., 2002). 
Cognitive Reserve Hypothesis 
Cognitive reserve (CR) refers the brain’s resistance to neuropathological damage and 
cognitive decline (Scarmeas et al., 2003). CR hypothesis suggests that there are individual 
differences in the progression of age-associated cognitive decline (Scarmeas et al., 2003). The factors 
that determine the differences in age-associated cognitive decline amongst individuals are not yet 
fully understood (Deary et al., 2009). However, some identified factors contributing to a large CR 
include involvement in higher education, above average estimated intelligence quotient, high 
occupational attainment, and regular engagement in leisure time activities such as PA (Tucker & 
Stern, 2011). Research suggests that those with greater CR are often less likely to experience 
accelerated cognitive decline than those with less CR (Tucker & Stern, 2011). Risk factors of 
cognitive decline can be environmental or genetic (Lim et al., 2014; Sofi et al., 2010). The 
identification of risk factors allows the synthesis of preventative measures and early interventions 
aimed at those most susceptible (Anstey & Christensen, 2000; Luck et al., 2014). 
Interventions may be aimed toward modifiable risk factors, such as environmental, lifestyle, 
or cultural behaviours and exposures that increase risk of cognitive decline (Lindsay et al., 2002). 
However, developing interventions is much harder for non-modifiable risk factors, such as genetic 
predisposition to disease, as they cannot be easily manipulated (Lindsay et al., 2002).  
The primary identified environmental protective factor against cognitive decline is PA, and 
the primary genetic risk factor for cognitive decline is being a carrier of one or more Apolipoprotein 
E epsilon 4 alleles, (Cedazo-Minguez, 2007; Wolk & Dickerson, 2010). 
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Physical Activity and Cognitive Decline 
PA increases cerebrovascular integrity, cellular regeneration, neural plasticity, long-term 
potentiation, neurotrophic changes, and decreases in stress and depression, which may in turn 
improve cognitive functioning (Chodzko-Zajko & Moore, 1994; Laurin et al., 2001; Praag et al., 
1999). To be considered physically active, one should engage in at least 150 minutes of moderate-
intensity PA (e.g. walking, cycling) or 75 minutes of vigorous PA (e.g. running, weight-lifting) per 
week (WHO, 2017). It is estimated that globally, over one quarter of adults are not active enough 
(WHO, 2017). This finding is particularly pronounced in older adults (Chodzko-Zajko, 2014). 
The majority of previous literature assessing protection against cognitive decline has focused 
on pharmaceutical interventions rather than potential protective environmental interventions such as 
PA (Laurin et al., 2001). Further, research has focused on the protective effects of PA and cognitive 
against pathological cognitive decline such as Alzheimer’s disease, largely ignoring age-associated 
declines (Laurin et al., 2001).  
  A meta-analysis conducted by Sofi et al. (2010) included 15 studies examining the effect of 
PA on cognitive functioning in cognitively healthy older adults. Results revealed that sedentary 
individuals were approximately 35% more likely to experience cognitive decline than their highly 
active peers. A subsequent meta-analysis conducted by Guure et al. (2017) found a similar protective 
effect of PA on cognitive decline. However, Guure et al.’s findings displayed a much larger 
protective effect of PA in cases of pathological cognitive decline compared to non-pathological 
decline. 
A meta-analysis conducted by Smith et al. (2010) examined 29 studies (participant N = 
2,049) assessing the protective effect of aerobic exercise interventions on cognitive functioning in 
adults. Trial periods ranged from six weeks to 18 months. Smith et al. found that subjects who 
engaged in the intervention displayed a modest improvement in attention, processing speed, and EF, 
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as compared to the control group. The improvements in WM however, were inconsistent (Smith et 
al., 2010). 
Colcombe and Kramer (2003) conducted a meta-analysis on the effectiveness of fitness 
interventions on EF in sedentary older adults. Findings revealed that EF was greatly improved from 
pre-test to post-test. These studies suggest that engaging in PA, even when implemented as an 
intervention in later life can protect various domains of cognitive functioning against cognitive 
decline, specifically fluid abilities such as WM and EF. However, longitudinal studies are needed to 
determine whether PA leads to long-term positive changes in cognitive functioning. As PA is a 
modifiable protective factor against cognitive decline, it may be delivered as an intervention to 
genetically susceptible populations to reduce risk of rapid age-associated cognitive decline. The most 
researched genetic risk factor for Alzheimer’s disease is being a carrier of the Apolipoprotein 4 
allele (Cedazo-Minguez, 2007). 
Apolipoprotein E 
Apolipoprotein E (apoE, protein; APOE, gene) is a polymorphic apolipoprotein that is 
primarily synthesized by astrocytes in the human central nervous system (Liu et al., 2015). The 
fundamental roles of apoE is to distribute lipids and cholesterol around the blood stream, lipid 
clearance, cellular recycling, synaptic plasticity, and membrane repair in the brain following injury 
(Leoni et al., 2010; Liu et al., 2013). The APOE gene has three common allelic variations: epsilon 2 
(2), epsilon 3 (3), and epsilon 4 (4), all producing proteins that differ slightly in structure (E2, E3, 
and E4 respectively; Marioni et al., 2016). As for all genetic inheritance, individuals inherit one 
allele from each parent, meaning individuals can carry one of six possible genotypes (2/2, 2/3, 
2/4, 3/3, 3/4, 4/4; Cedazo-Minguez, 2007). Carrying two alleles that are not the same (e.g. 
3/4) is referred to as a heterozygous genotype, a homozygous genotype occurs when both APOE 
alleles are the same (e.g. 4/4; Etiner et al., 2007). 
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APOE-3 is the most common allelic variation, as it is present in 77-78% of the global 
population (Cedazo-Minguez, 2007). Research has found no effect of APOE-3 on cognitive 
functioning, as compared to 2 and 3 alleles (Cedazo-Minguez, 2007). APOE-2 is present in an 
estimated 7-8% of the global population (Suri et al., 2015). APOE-2 has an identified a protective 
role for non-pathological cognitive decline and lowering risk of developing dementia (Martins et al., 
205). APOE-2 is also associated with longevity, fewer amyloid β plaques, reduced risk of cerebral 
amyloid angiopathy, greater cortical thickness, and larger hippocampal volume than 3 and 4 
carriers (Liu et al., 2013; Suri et al., 2015; Tirabosci et al., 2004).APOE-4 is present in an estimated 
14-16% of the population (Etiner et al., 2007). APOE-4 has been associated with cardiovascular 
disease, however it is best known as the primary genetic risk factor for developing Alzheimer’s 
disease, accelerated cognitive decline, and earlier onset of age-associated cognitive decline (Hee 
Kang et al., 2005; Wolk & Dickerson, 2010). The specific mechanism in which APOE-4 affects 
cognitive functioning is not fully understood, however it has been associated with increased amyloid 
β aggregation and reduced neurite growth as compared to 2 and 3 carriers (Mahley, Weisgraber, & 
Huang, 2006). 
 Individuals who inherit one or more APOE-4 allele (e.g. 3/4) are referred to as APOE-4 
carriers. Those who do not inherit the APOE-4 allele (e.g. 3/2) are referred to as APOE-4 non-
carriers. The protein APOE-4 (apoE 4) produces has the least stable structure, increased misfolding 
and a slightly different process of lipid binding as compared to those produced by 3 and 2 
(Mahley, Weisgraber, & Huang, 2008; Mahley et al., 2006). It has been argued that these structural 
differences may increase neurodegeneration (Mahley et al., 2006; Zhong & Weisgraber, 2009).  
Liu et al. (2013) found that non-carriers mean age of clinical onset of Alzheimer’s disease 
occurred at 84 years of age, heterozygous carriers at 76 years of age, and homozygous carriers at 68 
years of age. These findings suggest that homozygous carriers are at far greater risk for rapid and 
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early onset cognitive decline as compared with non-carriers and heterozygous carriers, therefore 
demonstrating a dose-dependent response. 
APOE-ɛ4 and Cognition 
 Previous literature has identified APOE-4 as the primary genetic risk factor for Alzheimer’s 
disease (Lui et al., 2013). It has also been suggested that APOE-4 has a negative effect on age-
associated non-pathological decline (Marioni et al., 2016). A cross sectional analysis conducted by 
Filippini et al. (2011) examined the effects of age and APOE genotype on brain activation. Filippini 
et al. assessed fMRI activation in an encoding memory task in a sample of healthy adults. Results 
suggested that ageing was associated with lower activation and cerebral blood flow in APOE-4 
carriers, compared with non-carriers. Fillipini et al. suggest that the decrease in activation may reflect 
vulnerability to late life-pathology, cognitive decline, and changes in brain functioning in APOE-4 
carriers. 
  Marioni et al. (2016) conducted a meta-analysis on the differential effects of the APOE-4 
allele on domains of cognitive functioning. Marioni et al.’s analysis consisted of 18,337 participants 
aged 18 - 94 years old (M = 47 years old, SD = 15 years). Results of a linear regression analysis 
revealed that APOE-4 was associated with lower performance on memory and processing speed 
tasks in participants aged over 60 years old, compared with non-carriers. Being an APOE-4 carrier 
was associated also with higher scores of verbal fluency and vocabulary (Marioni et al., 2016). Small 
et al. (2004) conducted a similar study, finding that APOE-4 carriers had poorer global cognitive 
functioning, episodic memory, and EF in older adults than non-carrier, however the effect sizes were 
trivial. 
These finding consistently indicate that with aging, fluid abilities are being affected by 
APOE-4 (WM, EF, and processing speed), whereas crystallised abilities appear to remain somewhat 
unaffected (verbal fluency and vocabulary; Salthouse, 2010).  
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It has been suggested that environmental factors such as PA and diet may influence genetic 
expression (Ordovas, 2007). Therefore, as interventions cannot alter genetic predisposition to 
disease, the focus must shift to the relationship between gene and environment (Jaenisch & Bird, 
2003). As APOE-4 is associated with poorer cognitive functioning, and PA is associated with 
improved cognitive functioning, the interaction between these factors and how they affect cognition 
may be of interest. 
Relationship between Physical Activity and APOE-4 
Rovio et al. (2005) conducted a longitudinal study investigating interaction of leisure-time 
activity and APOE-4 carrier status on dementia risk. Participants completed a PA questionnaire, two 
or more leisure-time activities per week was classified as active, and less than two times per week 
was considered inactive. Cognitive functioning was assessed by the Mini Mental Status Exam 
(MMSE). Results revealed that the active group had lower odds of developing dementia than the 
inactive group. Further, the protective effects of PA were more pronounced in APOE-4 carriers than 
non-carriers. However, these findings were not statistically significant following adjustments for age, 
sex, education, follow-up time, locomotor disorders, vascular disorders, smoking and alcohol 
consumption (Rovio et al., 2005). Yang et al. (2014) conducted a similar study, examining the 
interaction between leisure-time activities and APOE-4 carrier status on dementia risk. Results 
revealed that in APOE-4 carriers, only high-frequency PA (more than three times per week) showed 
protective effects on cognition. Conversely, all types of leisure activities showed a protective effect 
on cognitive decline in non-carriers (Yang et al., 2014).   
A limitation of Rovio et al.’s (2005) and Yang et al.’s (2014) findings may be that their cut-
off for what is considered physically active may have been too low, thus those considered active 
were possibly not active enough to gain health benefits. The Office of Disease Prevention and Health 
Promotion (ODPHP; 2017) state that total weekly PA should equate to 500-1000 METS to produce 
substantial health benefits in adults. METS refer to the ratio of energy expended during an activity to 
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the rate of energy expended at rest. An activity such as walking, may be a six MET activity, meaning 
it expends six times the energy used by the body at rest (ODHP, 2017). Thus, studies assessing the 
effects of PA may be more likely to find a significant effect if their definition of PA is meeting 
ODPHP’s (2017) guidelines. A further limitation of Rovio et al.’s (2005) and Yang et al.’s (2014) 
research is the focus on dementias such as Alzheimer’s disease, largely ignoring non-pathological 
cognitive functioning  
 Schuit et al. (2001) conducted a study assessing the effect of PA on cognitive decline in older 
adult APOE-4 carriers and non-carriers. Schuit et al.’s sample comprised of elderly Dutch men (N = 
347, mean age = 74.6 years old) who were tested in 1990 and again in 1993. Cognitive decline was 
assessed with the MMSE, defining a decline as a three point or more decrease between testing times. 
PA was categorised as active (more than an hour of PA per day), and inactive (less than one hour of 
PA per day). Schuit et al. adjusted for age, education, alcohol consumption, smoking status, and 
baseline cognitive functioning.  
The findings of Schuit et al.’s results revealed that the risk of cognitive decline was similar 
amongst active and inactive APOE-4 non-carriers, however, in carriers the risk of cognitive decline 
was four times greater when they were inactive compared to active. These findings suggest there is a 
relationship between PA and APOE, and that PA is particularly important in APOE-4 carriers. 
Furthermore, Schuit et al.’s results revealed that inactive carriers were 13.7 times more at risk for 
cognitive decline than active non-carriers.  
Schuit et al.’s (2001) findings facilitate the identification of subgroups that are most at risk 
for poor cognitive functioning in later life. Further, they suggest that physically inactive APOE-4 
carriers have the greatest risk of cognitive decline, and physically active non-carriers are least at risk. 
This finding has important implications for targeting preventive interventions. However, Schuit et 
al.’s findings are not without limitation. As the sample comprised only of males the results may not 
generalizable to females. This is of high importance, as sex differences in cognitive decline have 
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been reported, with females experiencing greater decline than males (Lipnicki et al., 2007). Thus, 
further research is required with a more representative sample to determine generalisability. A 
further limitation of Schuit et al.’s research is the use of the MMSE as a test of cognitive functioning. 
The MMSE is a relatively blunt tool that assesses general cognitive functioning rather than breaking 
it down into specific domains.  Thus, deficits in one area may be overwhelmed by strengths in 
another area.  
 Kivipelto et al. (2008) addressed some of these outlined limitations in their a study aimed to 
assess the interaction between environmental and genetic risk factors of cognitive decline. In this 
study, 1149 older adults completed the MMSE in 1977, and again in 1998. PA was categorised as 
‘active’ (more than 50 minutes of high intensity activity per week) or ‘inactive’ (less than 50 minutes 
per week). Kivipelto et al. found that APOE-4 carriers were significantly more likely to experience 
cognitive decline than non-carriers, regardless of PA level. In APOE-4 non-carriers, physical 
inactivity increased risk of cognitive decline by 1.8, indicating a very small effect. This suggesting 
that PA protected against cognitive decline in non-carriers. In active participants, APOE-4 carriers 
were 2.3 times more at risk for cognitive decline than non-carriers, indicating a small effect. 
Kivipelto et al. further found that inactive carriers were 5.5 times more likely to develop cognitive 
decline than active non-carriers, indicating a moderate effect. 
The findings of Kivipelto et al.’s (2008) study suggests that physical inactivity is a greater 
risk factor for cognitive decline in APOE-4 carriers than non-carriers. Kivipelto et al.’s sample was 
larger and more representative than, Schuit et al.’s (2001), yet similar results were found. However, 
these findings have small effect sizes questioning psychological significance. Further research has 
found conflicting results. 
 A prospective study by Podewils et al. (2005) conducted from 1992-2000 assessed the effect 
of PA and genotype on dementia risk. The study consisted of 3,375 older adults who completed the 
MMSE and the Minnesota Leisure Time Activity Questionnaire. Results revealed an inverse 
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relationship between PA and dementia risk for APOE-4 non-carriers (Podewils et al., 2005). 
However, no relationship was found between PA and dementia risk in APOE-4 carriers. Therefore, 
Podewils et al. concluded that PA only plays a protective role on non-4 carriers. Podewils et al. 
further argued that the effects of PA may be reflecting overall life engagement and social activity, 
rather than PA itself. Thus, future research is required to examine PA in isolation of potential 
confounds. An issue with Podewils et al.’s findings is the focus on dementia rather than age-
associated cognitive declines. Thus, the finding of a non-significant relationship between APOE-4 
carriers and PA has only been found in dementia studies, not in non-pathological studies. 
Podewils et al.’s (2005) findings are consistent with that of Obisesan et al. (2012), who 
reported that high PA was associated with better performance on variations of the MMSE in non-
carriers of APOE-4 aged 60-69 years old. However, Obisesan et al.’s results found that APOE-4 
carriers and non-carriers aged 70 years and older performed significantly better on the short MMSE 
when they were physically active compared to inactive. Obisesan et al.’s results revealed that 
inactive older APOE-4 carriers performed worse than active APOE-4 carriers and inactive APOE-
4 non-carriers, with active APOE non-4 carriers performing the best. These results suggest that the 
effect of APOE-4 may become more pronounced with age, allowing PA to have a larger modifiable 
effect in older age (Obisesan et al., 2012). Further, the interaction effect of PA and genotype was far 
more pronounced in the APOE-4 homozygote subgroup in comparison to the heterozygote 
subgroup (Obisesan et al., 2012), suggesting a dose-dependent effect. 
 An issue with the studies above is the use of the MMSE or the short MMSE to assess 
cognitive functioning. Whilst the MMSE is a reliable and valid measure, it is a relatively blunt tool 
(Tombaugh & McLyntyre, 1992). Tombaugh and McLyntyre (1992) state that the MMSE provides a 
brief overview of cognitive functioning but should not be used as a diagnostic tool for cognitive 
impairments. Further, the MMSE provides a global measure of cognitive functioning rather than 
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domain specific functioning. As highlighted previously, PA and APOE-4 have been shown to affect 
fluid cognitive abilities (WM, EF) more than crystallised abilities (LTM, learning). Thus, further 
research is required to determine which domains are most affected by genetic susceptibility, are most 
protected by PA, and which are most affected by the relationship between APOE-4 and PA so that 
effective interventions can be developed and targeted to groups that would benefit most. 
 In attempt to close this gap, Etiner et al. (2007) conducted a study to determine the effect of 
APOE genotype and aerobic fitness on domain specific facets of cognitive performance. Etiner et 
al.’s (2007) sample comprised of 90 cognitively normal older women. Participants completed a 
graded exercise test (GXT) to determine aerobic fitness. Participants completed an array of cognitive 
tests including the Rey-Auditory Verbal Learning Test (RAVLT), the Rey-Complex Figure Test 
(CFT), the Wisconsin Card-Sorting Task (WCST), and the Paced Auditory Serial Addition Task 
(PASAT). A regression analysis revealed that aerobic fitness was associated with significantly better 
performance on measures of LTM (RAVLT, RCFT) in APOE-4 homozygotes. Etiner et al. (2007) 
found a non-significant interaction between APOE-4 carrier status and aerobic fitness on measures 
of WM (PASAT) or EF (WCST). These findings are contrary to their hypotheses based on previous 
literature and theory, such as cognitive reserve hypothesis.  
A limitation Etiner et al.’s (2007) study is the small sample size (only eight APOE-4 
homozygotes included), and the sample being comprised of female subjects only. This small sample 
threatens statistical power, generalizability, and reliability of findings. Thus, a larger and more 
representative sample is needed that examines interaction of APOE-4 and PA on domain-specific 
cognitive functioning. 
Aim & Hypotheses 
 Findings of previous literature has looked at the effects on global cognitive functioning, as 
measured by the MMSE rather than domain-specific cognitive functioning. Further, the focus of 
previous literature has been on pathological decline, such as Alzheimer’s disease rather than age-
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associated cognitive decline. The research on age-associated cognitive decline is also both scarce and 
inconsistent. Therefore, the aim of the current study was to clarify the relationship between PA level 
and APOE-4 carrier status on cognitive performance in the domains of EF, LTM, learning, and WM 
in cognitively normal older adults.  The following hypotheses are proposed: 
1. It is hypothesised that individuals who report high levels of PA will perform significantly 
better on EF and WM tasks, as compared to those who report low PA. The effect of PA on 
LTM and learning is hypothesised to be non-significant. 
2. It is hypothesised that APOE-4 carriers will perform significantly worse than non-carriers on 
measures of EF, learning, LTM and WM.  
3. It is hypothesised that low PA APOE-4 carriers will perform significantly worse than high 
PA APOE-4 non-carriers on measures of EF, LTM, learning, and WM. 
Method 
Design 
 The current study is employs a cross-sectional between groups 2 (APOE-4 carrier status: 
APOE-4 carrier, non-4 carrier) x 2 (physical activity: low, high) design. The dependent variables 
(DVs) of the current study are domains of cognitive functioning; EF, LTM, learning, and WM. 
Participants 
 All participants in the present study had previously volunteered to participate in the 
Tasmanian Healthy Brain Project (THBP; ethics approval number: H11070), who were invited to 
participate in the current study. The THBP is an ongoing project aimed to examine the effect of 
education interventions in later life. Participants of the THBP have undergone genetic testing and 
annual tests of cognitive functioning. Participants of the present study were given the right to 
withdraw at any time and were not compensated for their time. The exclusion criteria include being 
aged under 50 years old and having a family history of Alzheimer’s disease. 36% of participants 
were carriers of the APOE-ε4 allele, whilst 64% were non-carriers.  
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The initial sample comprised of 225 participants, however 25 were excluded due to 
incompletion of all measures. The final sample comprised of two hundred participants (male N = 61, 
female N = 139) aged over 50 years old (mean age = 64.36, SD = 6.62 years) 
 Ethics approval was gained (approval number: H0016623), and all participants provided 
informed consent (see appendix A, B, and C).  All procedures were conducted in accordance with the 
APS Code of Ethics and Ethical Guidelines.  
Materials 
Incidental and Planned Exercise Questionnaire for older people (IPEQ-WA): The IPEQ-WA 
is a 10-item self-report questionnaire that requests participants to recall their estimated PA over the 
past three months (Delbaere, Hauer & Lord, 2010). The IPEQ-WA was chosen as it assesses PA 
estimates of participants’ usual week of PA (Delbarere et al., 2010). ‘Usual week’ questionnaires 
often demonstrate better psychometric properties than a questionnaires assessing past week PA, 
which is the focus of most PA scales (Doma et al., 2017).  Responses are recorded on a Likert scale 
from 1-7, where 1 indicates physical inactivity, and 7 indicates high PA. The IPEQ-WA has good 
reliability and validity in geriatric populations (Merom et al., 2014). The IPEQ-WA was 
administered online via SurveyMonkey and is estimated to take approximately 10 minutes to 
complete. 
The following battery of neurocognitive assessments were undertaken as part of the 
Tasmanian Healthy Brain Project: 
Hospital Anxiety and Depression Scale (HADS): The HADS is a self-assessment 
questionnaire that detects symptoms of depression and anxiety (Zigmond & Snaith, 1983). The 
HADS contains 14 items, seven assessing depressive symptoms, seven assessing symptoms of 
anxiety. Items are scored from 0-3, where a score of 0 indicates low depression or anxiety, and items 
scored as 3 indicate high depression or anxiety. The HADS is a generally valid and reliable measure 
in geriatric samples (Helvik et al., 2011), and takes approximately 5 minutes to administer. 
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Weschler Test of Adult Reading (WTAR): The WTAR is a neurocognitive assessment 
designed to predict intellectual performance in adults (Weschler, 2001). The WTAR has good 
reliability and validity (Whitney et al., 2010). When completing the WTAR, the participant is asked 
to read aloud 50 words of increasing difficulty. Correct pronunciation is given a score of one, 
incorrect pronunciation is given a score of zero. The results are averaged and co-normed with the 
Weschler Adult Intelligence Scale (WAIS) to derive as estimated full-scale intelligence quotient 
(FSIQ), whereby higher scores indicate greater estimated FSIQ.  The WTAR takes approximately 
five minutes to administer. 
Controlled Oral Word Association Test (COWAT): The COWAT is a reliable assessment of 
verbal processing and verbal fluency, which are both aspects of EF (Ross et al., 2007).  When 
administering the COWAT, the test administrator presents the participant with three letters (F, A, S). 
The participant is given 60 seconds to list as many words as they can that starts with the letter 
presented. All words correctly recited across the trials are summed to obtain a total score, whereby 
higher scores indicate greater EF. The COWAT takes approximately 5 minutes to administer.  
Trail Making Test (TMT): The TMT assesses visual attention and task switching, which are 
both measures of EF (Christidi et al., 2013). The TMT is administered in two parts (A and B). The 
current study only examined part B of the TMT. TMT B instructs the participant to connect letters 
and the numbers in ascending order (A-1-B-2-C-3-D-4 and so on) (Christidi et al., 2013). The TMT 
is scored by time taken to complete the task, whereby longer time indicates poorer EF. The TMT 
generally has high reliability and takes approximately 2-5 minutes to administer (Christidi et al., 
2013).  
Victoria version of the Stroop Colour-Word Test (VST): The VST assesses selective attention 
and cognitive flexibility, which are both aspects of EF (Stroop, 1935; Spreen & Strauss, 1998). The 
VST is a 24-item task that involves three stimulus cards being presented sequentially. Stimulus card 
one contains coloured dots (blue, green, red, or yellow). The participant must as quickly as possibly 
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name the colour of the dots. Stimulus card two contains common words (such as; when, over, hard) 
printed in coloured ink. In this task, the participant is prompted to name the colour of the ink of each 
word as quickly as possible. Stimulus card three contains the names of colours printed in non-
corresponding ink colour. In this task, participants must name the colour of the ink of each word, 
ignoring the word itself. In the current study ‘Stroop interference’ was recorded, referring to the 
difference in reaction time between stimulus one and stimulus three (Malek et al., 2013). Larger 
Stroop interference scores indicated poorer EF. The VST takes approximately five minutes to 
administer. The VST is a common and valid neurocognitive evaluation often used in geriatric 
populations and in those suffering dementia (Bayard et al., 2011). 
Rey-Auditory Verbal Learning Test (RAVLT): The RAVLT assesses verbal learning and LTM 
via examining the participants’ ability to store, encode, combine, and recover verbal information 
(Fard et al., 2016). The RAVLT consists of 15 words which are read to the participant. The 
participant must then recite all the words they can remember from the list. This is repeated for five 
trials. To assess verbal learning, the increase of scores from trial one to five is recorded. Larger 
increase indicates stronger learning. To assess LTM the experimenter reads a second list of 15 words 
to the participant, this is referred to as the ‘distractor list’; aiming to remove items from the first list 
from the participants’ WM. Once the participant has recalled as many words as they can from the 
distractor list, they must recall as many words as they can from the initial list, without this list being 
presented again. The aim of this procedure is to assess how many words from the initial list have 
been consolidated to LTM, where higher scores indicate greater LTM for verbal information.  The 
RAVLT takes approximately 15 minutes to administer. 
Rey-Complex Figure Test (RCFT): The RCFT assesses non-verbal LTM (Meyers & Meyers, 
1995). The RCFT requires a participant to view a complex figure stimulus card, and copy the image 
onto a sheet of paper. Three minutes later, the participant is prompted to draw the image entirely 
from memory. Thirty minutes later, the participant is asked once again to draw the image entirely 
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from memory. Each drawing is scored for the accurate placement of 18 design elements of the 
complex figure. Higher scores of the RCFT indicate greater LTM capacity for non-verbal 
information. The RCFT takes approximately 45 minutes to administer (Meyers & Meyers, 1995).  
The Digit Span Test (DSP): The DSP is a subtest of the 3rd edition of the Weschler Adult 
Intelligence Scale (WAIS-III; Weschler, 1997). The DSP assesses working memory capacity. The 
administrator reads aloud a sequence of numbers that the participant must recall. If the participant 
recalls the list correctly, they are given a longer list. The maximum amount of numbers the 
participant can recall over two trials is recorded (Weschler, 1997). Higher scores indicate greater 
WM capacity. The DSP takes approximately 5 minutes to administer.  
Letter-Number-Sequencing (LNS): The LNS task is part of the WAIS-III (Weschler, 1997). 
The LNS primarily assesses WM. The administrator reads aloud a random sequence of letters and 
numbers (e.g. J, 9, X, 3). The participant must recall the letters in alphabetical order and the numbers 
in ascending order (e.g. 3, 9, J, X). Higher scores indicate greater WM capacity. The LNS takes 
approximately 5 minutes to administer. 
Procedure 
 Participants of the Tasmanian Healthy Brain Project (THBP) that had completed annual 
cognitive assessments and had previously had genetic data extractions were invited to participate in 
this study (N = 344).  Participant were informed of the current study through email and postal 
mailout. The email contained a link redirecting them to SurveyMonkey where they were provided 
with an information sheet (see appendix A), a consent form (see appendix B), and the IPEQ-WA (see 
appendix C).  Participants who requested a hard copy questionnaire were sent the written invitation, 
information sheet, consent form, IPEQ-WA, and postage-paid envelope that could then be mailed 
back to the University of Tasmania upon completion. Participants were requested to release their de-
identified cognitive and genetic data as part of the consent process. 
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In order to maintain the confidentiality clause which was part of the THBP original ethics 
approval, participant details were de-identified prior to release to the current study.  Completed 
surveys were initially received by the project manager of the THBP (Dr Kim Stuart), who removed 
identifying information (i.e. names as provided during the consent process), and replaced them with 
an alphanumeric code for each participant. This master code is only available to the project manager 
of THBP. Genetic data was extracted via saliva samples following Donohoe et al.’s method (1999). 
Cognitive data and genetic data was extracted from the THBP database and released to the current 
study, with the alphanumeric code attached to allow the PA results and cognitive and genetic data to 
be combined. To ensure security of collected data, hardcopies were kept in a lock safe drawer and 
electronic data was kept in a password protected Excel file. 
Data Screening and Analysis  
Participants were grouped by genotype (APOE-4 carrier, APOE-4 non-carrier) and by PA 
level (low, high). Exercises noted in the IPEQ-WA were calculated as metabolic equivalents (METS) 
following Ainsworth et al.’s (2011) compendium. Total weekly PA in the range of 500-1,000 METS 
is estimated to produce health benefits for adults (ODPHP, 2017). As people are known to inflate 
responses regarding self-reported PA, per social desirability bias (Adams et al., 2005), high PA was 
defined as more than 1000 METS per week, and low PA was defined as less than 1000 METS per 
week. 
SPSS version 24 was used to conduct all analyses. Chi Square tests of independence were run 
to determine whether there were any significant differences in frequencies APOE-ε4 carriers and 
non-carriers according to different demographic information (sex, control and experimental condition 
at the THBP and low and high PA status). Independent samples t-tests were run to determine whether 
there were any significant differences between APOE-ε4 carriers and non-carriers in education, age, 
estimated FSIQ, Body Mass Index (BMI), and the anxiety and depression subscales of the HADS.  
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Tests of normality and skewness indicated that in all measures of cognitive functioning, the 
distribution deviated from normal. Logarithmic and square root transformations were performed to 
control for skew. As ANOVAs are robust against breaches of normality (Field, 2009) and the 
transformations did not significantly alter the results, the untransformed data was used in the final 
analysis. Outliers were present; however, no outliers were more than two standard deviations from 
the mean, thus they were not removed or transformed in order to maintain power with larger samples 
(Field, 2009).  
 Correlations were run to assess the relationship between age and cognitive functioning, as 
previous literature has suggested that age-associated cognitive decline is far more pronounced in 
elderly samples (75 years and older) as compared to older adults (65 years and older) (Obisesan et 
al., 2012). Results revealed that as age increased, performance in some measures of EF (TMT) LTM 
(RAVLT, RCFT), learning (RAVLT), and WM (LNS) were significantly affected.  
 
Table 1. Correlations between Age and Cognitive Functioning 
Cognitive Function Measure Correlation (r) with Age 
EF COWAT -.088 
 TMT B 
VST inference 
.379** 
.212**  
LTM  RAVLT total  -.325** 
RCFT delayed -.317** 
WM DSP -.098 
LNS -.268** 
Note: * significant at  = .05, ** significant at  = .01 
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Due to the significance of the relationship between age and cognitive functioning, age was 
included as a covariate. A series of 2 (APOE-ε4 carrier status: carrier, non-carrier) x 2 (Physical 
activity level: low, high) factorial ANCOVAs were run to assess each neurocognitive assessment. EF 
was assessed by the TMT, VST, and COWAT. LTM was assessed by the RAVLT and RCFT, and 
WM was assessed by the DSP and LNS. A 2 (APOE-ε4 carrier status: carrier, non-carrier) x 2 
(Physical activity level: low, high) repeated measures ANCOVA was run to assess the differences 
between groups of the RAVLT learning curve from trial one to trial five to assess learning. 
Allelic frequencies were examined using the Hardy-Weinberg Equilibrium chi-square 
analysis (Emigh, 1980). The analysis revealed no significant differences in observed and expected 
frequencies (Eisenberg, Kuzawa, & Hayes, 2010) of APOE alleles, χ2 (5) = 1.90, p = .820 (see Table 
2). This suggests the current sample is representative of world allelic frequencies.  
 
Table 2. Apolipoprotein E Allelic Frequencies: Estimated vs. Observed 
 2/2 2/3 2/4 3/3 3/4 4/4 
Worldwide proportion estimate (%) .1 11.6 2.2 60.1 23.2 2.2 
Sample proportion (%) 0.0 9.5 3.5 54.5 28.5 4.0 
 
Results 
 The demographic data for the final sample is provided in Table 3. As demonstrated, there 
were no significant differences between APOE-ε4 carriers and non-carriers for age, sex, estimated 
FSIQ, HADS anxiety and depression scores, higher education, physical activity, body mass index 
(BMI), or placement in the THBP control or experimental education condition. Significantly more 
APOE-ε4 non-carriers had completed grade 12 than carriers. However, education was not considered 
as a covariate for this study as there were no significant differences in estimated FSIQ as measured 
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by the WTAR between genotype groups, and all participants had completed multiple units at the 
University of Tasmania. 
 
Table 3. Demographic Information between APOE-4 Carriers and Non-carriers 
Note: * = significant difference between carriers and non-carriers at α = .05 
THBS: the Tasmanian Healthy Brain Project, FSIQ: full-scale intelligence quotient estimate, BMI: 
body mass index 
 
Results of the ANCOVAs revealed no significant main effects of genotype on the battery of 
neurocognitive tests used (see Table 4 for descriptive statistics stratified by PA level, see Table 5 for 
 Non-Carrier 
N = 128 
Carrier 
N = 72 
t-test/χ2, (df) p 
Education (years) 
    < Grade 12 
 
11.38 (.90) 
 
11.19 (1.08) 
 
t (126) = 1.25 
 
.212 
    Further education 5.37 (2.71) 4.49 (2.50)  t (195) = 2.25 .026 
Age (years) 63.88 (6.58) 64.82 (6.12) t (198) = -.98 .328 
Gender     
    Male N (%) 43 (33.6%) 18 (25.0%) χ2 (1) = 1.61 .205 
    Female N (%) 85 (61.2%) 54 (75.0%)   
THBS Group N (%) 
    Experimental 
 
103 (80.5%) 
 
55 (76.4%) 
 
χ2 (1) = .46 
 
.497 
    Control 25 (19.5%) 17 (23.6%)   
Physical Activity 
    High N (%) 
 
97 (75.8%) 
 
54 (75.5%) 
 
χ2 (1) = .015 
 
.902 
    Low N (%) 31 (24.2%) 18 (25.0%)   
FSIQ M (SD) 44.73 (4.52) 43.54 (5.60) t (198) = 1.64 .102 
BMI M (SD) 26.69 (5.52) 27.97 (14.17) t (196) = -.91 .362 
Anxiety M (SD) 4.41 (3.32) 4.82 (3.06) t (198)  = -.85 .395 
Depression M (SD) 1.96 (2.25) 2.26 (2.46) t (198) = -.88 .378 
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descriptive statistics stratified by genotype, see Table 6 for all ANCOVA inferential statistics, see 
table 7 for all descriptive statistics stratified by genotype and PA level). 
 
 Table 4. Means and Standard Deviation of the Main Effect PA Level on a Battery of Neurocognitive 
Tests 
 
Table 5. Means and Standard Deviation of the Main Effect of APOE-4 Carrier Status on a Battery 
of Neurocognitive Tests 
         Low PA            High PA 
  M SD  M SD 
EF COWAT 51.49 9.73 52.17 12.03 
 TMT B 56.94 20.11 55.43 23.65 
 Stroop Interference 1.81 0.35 1.84 9.48 
LTM  RAVLT total 51.09 8.91 53.22 10.29 
RCFT delayed 28.30 6.10 28.75 5.91 
WM DSP 18.83 3.72 18.85 3.95 
 LNS 11.75 2.44 11.92 2.39 
         Non-Carrier            Carrier 
  M SD  M SD 
EF COWAT 52.56 10.54 51.31 11.46 
 TMT B 55.30 23.57 56.16 24.93 
 Stroop Interference 1.80 .35 1.90 .42 
LTM  RAVLT total 52.79 9.03 51.78 10.29 
RCFT delayed 28.41 5.87 29.31 6.15 
WM DSP 18.87 3.80 18.79 3.89 
 LNS 11.89 2.40 11.89 2.40 
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Table 6. ANCOVA Results for the Interaction between APOE- 4 Carrier Status and Physical 
Activity on a Battery of Neurocognitive Assessments.
 
 
 
Cognitive Function Variable df 
within, error 
F p d 
Long-term memory 
and Learning 
RAVLT Total 
    APOE- 4 Carrier Status 
 
1, 195 
 
0.00 
 
.969 
 
.11 
     Physical Activity Level 1, 195 0.99 .321 .20 
     APOE-4 * PA 1, 195 0.37 .542 .21 
 RCFT Delayed 
    APOE-4 Carrier Status 
 
1, 195 
 
3.77 
 
.054 
 
.15 
     Physical Activity Level 1, 195 0.00 .991 .04 
     APOE-4 * PA 1, 195 2.12 .147 𝜂𝜌2 = .011 
Working Memory DSP 
    APOE-4 Carrier Status 
 
1, 195 
 
       0.39 
 
.533 
 
.02 
     Physical Activity Level     1, 195 0.42 .517 .05 
     APOE-4 * PA 1, 195 1.64 .202 𝜂𝜌2 = .008 
 LNS 
    APOE-4 Carrier Status 
 
1, 195 
 
0.00 
 
.984 
 
.09 
     Physical Activity Level     1, 195 0.13 .715 .02 
     APOE-4 * PA 1, 195 0.43 .514 𝜂𝜌2 = .002 
Executive 
Functioning 
COWAT 
   APOE-4 Carrier Status 
 
1, 195 
 
0.01 
 
.940 
 
.15 
    Physical Activity Level 1, 195 0.27 .608 .03 
    APOE-4 * PA 1, 195 1.30 .255 𝜂𝜌2 = .007 
 TMT B 
    APOE-4 Carrier Status 
 
1, 194 
 
0.09 
 
.766 
 
.01 
     Physical Activity Level 1, 194 0.03 .855 .00 
     APOE-4 * PA 1, 194 0.67 .414 𝜂𝜌2 = .003 
 Stroop Interference 
     APOE-4 Carrier Status 
 
1, 194 
 
2.41 
 
.122 
 
.01 
      Physical Activity Level 1, 194 .25 .619 .08 
      APOE-4 * PA 1, 194 .08 .076 𝜂𝜌2 = .000 
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Table 7. Descriptive Statistics for Cognitive Function of APOEɛ4 Carriers and Non-carriers, Stratified by Physical Activity Level 
 
Note: COWAT: Controlled Oral Word Association Test, TMT B: Trail Making Test B, VST I: Victoria 24-Stroop task inference, RAVLT T: 
Rey-Auditory Verbal Learning Test total, RCF DT: Rey-Complex Figure Test delayed, DSP: Digit Span test, LNS: Letter-Number Sequencing.
  Low PA    High PA  
Non-Carrier 
N = 31 
Carrier 
N = 18 
 Non-Carrier 
N = 97 
Carrier 
N = 54 
 M (SD) 95% CI M (SD)   95% CI M (SD)  95% CI M (SD)  95% CI 
COWAT 51.68 (7.84) [47.82, 55.54] 53.61 (11.27) 
59.36 (23.72) 
1.89 (.38) 
51.22 (10.53) 
30.31 (4.90) 
19.72 (3.20) 
11.94 (2.34) 
[48.55, 58.68] 52.85 (11.29) 
55.91 (25.24) 
1.81 (.35) 
53.38 (9.20) 
28.75 (5.80) 
18.96 (3.70) 
11.92 (2.33) 
[50.66, 55.03] 50.54 (11.53) 
55.10 (25.45) 
1.90 (.44) 
51.96 (10.29) 
28.97 (6.52) 
18.48 (4.07) 
11.57 (2.48) 
[47.61, 53.46] 
TMT B 53.40 (17.61) [44.84, 61.95] [48.13, 70.58] [51.05, 60.77] [48.61, 61.58] 
VST I 1.76 (.34) [1.63, 1.89] [1.71, 2.06] [1.73, 1.88] [1.80, 2.00] 
RAVLT T 50.94 (8.32) [47.57, 54.30] [46.80, 55.64] [51.48, 55.29] [49.41, 54.51] 
RCFT D 27.36 (6.08) [25.24, 29.47] [27.53, 33.08] [27.55, 29.94] [27.37, 30.58] 
DSP 18.55 (4.12) [17.19, 19.91] [17.94, 21.50] [18.19, 19.73] [17.45, 19.51] 
LNS 11.81 (2.64) [10.95, 12.66] [10.82, 13.07] [11.43, 12.40] [10.92, 12.22] 
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Cognitive functioning was assessed via a series of factorial ANCOVAs and one repeated 
measures ANCOVA (see Table 5 for all inferential ANCOVA statistics and Table 6 for all 
descriptive statistics). 
2 (APOE-4 carrier status: carrier, non-carrier) x 2 (PA level: low, high) ANCOVAs were 
run to assess the main effects and interactions of APOE-4 carrier status and PA level on EF, as 
measured by the COWAT, TMT B, and VST tasks. Results revealed non-significant main effects or 
interactions of APOE-4 and PA on any measures of EF with trivial effect sizes. 
2 (APOE-4 carrier status: carrier, non-carrier) x 2 (PA level: low, high) ANCOVAs were 
run to assess the main effects and interactions of APOE-4 carrier status and PA level on LTM. 
Results revealed non-significant main effects or interactions of APOE-4 and PA on any measures of 
LTM with trivial to small effect sizes. 
A 2 (APOE-4 carrier status: carrier, non-carrier) x 2 (PA level: low, high) repeated measures 
ANCOVA was run to assess the learning curve of the RAVLT from trial one (M = 6.58, SD = 1.93) 
to five (M = 12.79, SD = 2.14). As there were more than two levels of the dependent variable, 
Mauchley’s test of sphericity was violated, W(9) = .78, p = <.001. Therefore, a greenhouse geisser 
epsilon correction was applied. Results revealed that overall, performance significantly improved 
from trial one of the RAVLT to trial five, demonstrating a large effect, F(3.5, 693) = 565.23, p = 
<.001, 𝜂𝜌2 = .743. Results revealed a non-significant main effect of PA, F(3.5, 693) = 2.32, p = .064, 
𝜂𝜌2 = .012 with a small effect size. Results revealed a non-significant main effect of APOE-4 carrier 
status on the RAVLT learning curve F(3.5, 693) = 0.36, p = .814, 𝜂𝜌2 = .002 with a trivial effect 
size. Further, the results revealed a non-significant interaction between APOE-4 carrier status and 
PA in learning F(3.5, 693) = .50, p = .710, 𝜂𝜌2 = .003, with trivial effect sizes (see Figure 1).   
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Figure 1.  Mean Score on the RAVLT from Trial 1-5 of Low and High PA APOE-4 
 Carriers and Non-Carriers  
 
 
 
2 (APOE-4 carrier status: carrier, non-carrier) x 2 (PA level: low, high) ANCOVAs were 
run to assess the main effects and interactions of APOE-4 carrier status and PA level on WM, as 
measured by the DSP and LNS tasks. Results revealed non-significant main effects and interactions 
of APOE-4 and PA on any measures of WM with trivial effect size. 
These findings suggest that there is no statistically or psychologically significant effect of 
APOE-4, PA, or the relationship between APOE-4 and PA on EF, LTM, learning, or WM.  
Yang et al. (2014) found that the interaction APOE-4 carrier status and PA on cognitive 
functioning, until PA was non-significant in high PA versus low PA groups. However, when PA was 
categorised as ‘vigorous’ versus ‘sedentary, the interaction became significant. Therefore, A 2 (PA: 
very low, very high) x 2 (APOE-4 carrier status: carrier, non-carrier) ANCOVA was run to 
determine whether vigorous PA (over 2000 METS) and very low PA (less than 500 METS) had 
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more pronounced effects than high (over 1000 METS) and low (less than 1000 METS) PA. 
However, results revealed no significant differences, thus the original ANCOVAs were analysed to 
obtain a larger sample size and maintain statistical power.  
 
Discussion 
The majority of previous literature has assessed the relationship of APOE-4 and PA on 
global cognitive functioning (as measured by the MMSE), finding inconsistent results (Kivipelto al., 
2008; Podewils et al., 2005). Further, most pre-existing literature that has investigated this 
interaction has done so in pathological cases rather than age-associated cognitive decline (Luck et al., 
2014). The current study is the first to examine the relationship between PA level and APOE-4 
carrier status on cognitive performance in the domains of EF, LTM, learning, and WM in cognitively 
healthy male and female older adults. Therefore, whilst the hypotheses were derived from pre-
existing theory and literature, the findings of this research are primarily exploratory. 
Findings 
  Results of the present study revealed that the main effect of PA on all domains of cognitive 
functioning was non-significant. Therefore the hypothesis that the high PA group will perform 
significantly better than the low PA group on EF and WM tasks, with no significant differences on 
LTM and learning tasks was only partially supported.  
The results of the present study revealed that the main effect of APOE-4 was non-significant 
across all domains of cognitive functioning. Therefore, the hypothesis that 4 carriers will perform 
significantly worse than 4 non-carriers on all measures of cognitive functioning was not supported.  
The interaction between APOE-4 carrier status and PA level was non-significant on all 
domains of cognitive functioning. Therefore, the hypothesis that low PA APOE-4 carriers will 
perform significantly worse than high PA APOE-4 non-carriers across all measures of cognitive 
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functioning was not supported. Furthermore, all effect sizes (Cohen’s d and 𝜂𝜌2) were trivial to very 
small, revealing no psychologically significant findings. 
 These results suggest that there is a non-significant effect of PA or of APOE-4 on cognitive 
functioning. These finding further suggest that PA may not affect the expression of APOE-4 on 
cognitive functioning, thus there may not be a gene environment interaction affecting older adults’ 
cognitive functioning across the domains of EF, LTM, learning, or WM. 
(In)Consistencies with Previous Literature 
Whilst previous literature has typically found an interaction between APOE-4 and PA on 
cognitive functioning, the direction of the relationship has not always been consistent and the effect 
sizes have often been small (Wisdom, Callahan, & Hawkins, 2011). For example, Podewils et al. 
(2005) found that PA only improved cognitive performance in APOE-4 non-carriers, whereas 
Schuit et al. (2001) found PA to have a much greater protective effect on APOE-4 carriers than non-
carriers. Therefore, it is important to emphasise that in this area of research, no pattern of results 
have been found consistently (Luck et al., 2014).   
Results of the current study are somewhat consistent with Etiner et al.’s (2007) research. 
Etiner et al. found no significant result for heterozygous APOE-4 carriers on EF, WM, or LTM. 
However, Etiner et al. did find that physically fit APOE-4 homozygous carriers performed 
significantly better on LTM tasks than physically unfit APOE-4 carriers. Etiner et al.’s sample was 
small and comprised of females only (N = 90, mean age = 61 years old), thus the findings of the 
current study may be more generalizable, as a larger and more representative sample was used.  
Results of the present study are also somewhat consistent with Rovio et al.’s. (2005) and 
Kivipelto et al.’s (2012) results, finding non-significant interactions between PA and APOE-4 after 
applying adjustments for age, sex, education, follow-up time, locomotor disorders, vascular 
disorders, smoking and alcohol consumption on global cognitive decline. Both studies’ results 
revealed PA to have a protective effect on cognition, and APOE-4 to have a negative effect on 
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cognition. Further, both Kivipelto et al. and Rovio et al. found that inactive APOE-4 carriers were at 
greater risk than active carriers, followed by inactive non-carriers, followed by active non-carriers. 
This pattern of results was not present in the current study (see Table 7). Group means of the current 
study were very similar, with no group consistently performing better or worse than others amongst 
multiple tests of cognitive functioning. Thus, susceptibility to environmental manipulations and 
vulnerability to cognitive decline in certain groups could not be identified. 
Results of the current study are inconsistent with Podewils et al. (2005), Yang et al. (2014), 
and Obisesan et al. (2012) resulting, as they all found a significant interaction between APOE-4 and 
PA on cognitive functioning, with PA having the largest protective effect on non-carriers.  
Contributions and Strengths of the Current Study 
The majority of previous literature has primarily assessed the effects of APOE-4 in relation 
to patients suffering dementia (Brayne et al., 2007). However, research regarding age-associated 
cognitive functioning and decline is scarce (Brayne et al., 2007). Studies that have assessed the 
differences between pathological and non-pathological cognitive decline have identified much larger 
protective effects of PA and stronger interactions between APOE-4 and PA in pathological cases 
compared to non-pathological cases (Guure et al, 2017).  Therefore, a potential explanation for the 
disparity in results between previous literature and the current study may be the differential effects of 
APOE-4 and PA between pathological and non-pathological cognitive functioning. This finding 
suggests that APOE-4 and PA have no effect on cognitive functioning in healthy older adults, only 
in pathological cases.  
Another potential reason for the disparity of results between both previous studies and the 
current study is their design and analysis. The current study was a cross-sectional design, meaning 
that it assessed cognitive functioning at one static time-point. This design may produce different 
results to those using a longitudinal design, or a pre-test post-test design involving a PA intervention. 
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A common issue with genetic studies is the low frequency of alleles of interest leading to 
small or unequal group sizes (Dick et al., 2015). Dick et al. state that candidate gene studies where N 
= less than 1,000 are largely underpowered, thereby increasing the likelihood of revealing a false 
positive result (type II error) (Dick et al., 2015). This may mean that significant results of previous 
literature with smaller sample sizes may not reflect true differences in the population.  This is also a 
limitation for the current study, as will be discussed below. These finding may be further emphasised 
by publication bias leading to significant findings being more likely to be published than non-
significant findings (Dick et al., 2015). Therefore, though there is a lack of published non-significant 
relationships between PA, APOE-4, and cognitive decline, does not necessarily mean that these 
effects have not been found by previous researchers.  
Most of the previously outlined literature has assessed cognitive functioning using the 
MMSE, and has employed varying cut-off points to establish decline. Podewils et al. (2005) 
classified cognitive decline as a three point or more decrease, whilst Kivipelto et al. (2012) defined a 
decline as a five point or more decrease on the MMSE. This may be a potential explanation for the 
disparity of results in both previous literature and in the present study. In attempt to overcome this 
limitation of previous literature, the current study took a domain-specific approach rather than 
relying on the MMSE. This approach is far more in depth than the relatively blunt MMSE, as it 
allows for the potential identification of specific cognitive strengths and weaknesses Tombaugh & 
McLyntyre, 1992). Domain-specific tests also facilitate the identification of which domains of 
cognitive functioning may be the most and least affected by APOE-4, PA, and the relationship of 
both (Tombaugh & McLyntyre, 1992). Thus, the testing of cognitive functioning was a major 
strength for the current study. 
The PA questionnaire used in the present study (IPEQ-WA) has been cross-validated with 
objective measures of PA and was designed to measure PA in geriatric populations (Delbaere et al., 
2010). This is considerable of the current study, as what is considered physically active compared to 
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inactive varies greatly amongst previous studies. The majority of previous literature in this field has 
assessed participants’ past week of PA via self-reported, unstandardized questionnaires that have not 
been designed or validated for use in geriatric populations (Podewils et al., 2005). A primary 
problem with this assessment technique is that a participant’s past week of PA may not be 
representative of their normal week (Doma et al., 2017). Furthermore, previous literature has found 
that not all forms of PA produces health benefits (Watts et al., 2013), with vigorous activities such as 
weight lifting leading to much greater health benefits than low intensity activities such as walking 
(Yang et al., 2014). In attempt to overcome the limitations of PA measure found in previous 
literature, the current study calculated the METS of physical activities listed in the survey and 
implemented a high cut-off point for what was considered ‘active’ (ODPHP, 2017). Given that much 
of the previous literature has included low-intensity PA and has not calculated METS, this disparity 
in PA classification may account for some discrepancy in the results of previous literature (Podewils 
et al., 2005). Another limitation of previous literature’s PA measure is the reliance on the recall of 
past PA in a geriatric sample. This is somewhat overcome in the current study by using a 
questionnaire requesting ‘usual week’ PA as compared to ‘past week’ questionnaires, relying less on 
specific memory and more on estimates (Doma et al., 2017). 6t5 
Limitations 
One of the primary limitations the current study faces is the methodological design. A cross-
sectional approach allows identification of current cognitive functioning, however a longitudinal 
approach would have permitted detection of differences in trajectories of decline, should they exist. 
Therefore, groups with the best and poorest current performance can be identified, but the rate of 
decline, and scope of decline cannot be determined.  
Though the sample size of the current study was not particularly small (N = 200), once 
stratified into four groups, some groups were relatively small (e.g. low PA APOE-4 non-carriers N 
= 18). This led to uneven groups, threatening the robustness of ANCOVAs, and low post-hoc 
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statistical power (Dick et al., 2015; Field, 2009). This is a common problem in genetic and 
biomedical science, as allelic frequencies in the general population are low (i.e. APOE-4 only 
present in 15% of the general population), samples often have a low frequency of APOE-4 carriers 
(Dumas-Mallet et al., 2017; Etiner et al., 2015). Thus, larger studies are needed to allow a more 
robust exploration of this relationship. 
A further limitation of the current study is that over two thirds of the sample were categorised 
as engaging in high PA. Considering that over one quarter of adults are estimated to be physically 
inactive globally (WHO, 2017), this incidence of high PA versus low PA participants seems atypical. 
Per social desirability bias, participants are prone to over-inflation of PA estimates (Adams et al., 
2005). This means that those categorised as highly physically active may not have truly been. 
However, the cut-off set for what constitutes as highly active (1000 METS or more) was set at the 
maximum recommended METS (1000 METS or more) by ODPHP (2017) in attempt to overcome 
this limitation. This cut off point means that estimates from sedentary participants would have to be 
extremely inflated to appear as highly active in the current study. Further, when only very high PA 
(> 2000 METS vs < 500 METS) was compared to very low PA, the results remained non-significant, 
suggesting bias doesn’t fully account for the null findings. Another potential explanation for this 
stratification of PA level may be due to participation bias (Barreto et al., 2012). Participation bias 
argues that people who are motivated to volunteer to participate in studies assessing PA are 
significantly more physically active than those who do not.  
Future Research 
 There is no prevailing pattern of results that clearly defines the relationship between  
PA, APOE-4, and non-pathological cognitive functioning. Therefore, future research is required to 
clarify these effects and interactions. Future research should aim to investigate the potential 
differences in the relationship between PA and APOE-4 between dementia versus age-associated 
cognitive decline. This research may be beneficial in understanding the gene environment interaction 
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of cognitive functioning, and may help determine whether there truly is no effect of PA and APOE-
4 on non-pathological cognitive functioning. 
There are a number of methodological issues that could be addressed in future research in this 
area.  For one, future research should aim to conduct large-scale studies employing interventions or a 
longitudinal design.  Further, as age was a covariate of the current study, and Obisesan et al. (2012) 
found the effect of PA to impact APOE-4 differently at different age intervals, future research may 
benefit from including age as an independent variable, comparing those aged 60-69 years old to 
those aged 70 years and older. For a more evenly stratified sample regarding PA, future research 
should aim to recruit participants from a range of samples, as the participants of the THBP are 
particularly motivated to participate (Barreto et al., 2012). This may also be achieved by 
implementing a quota of active versus inactive participants, only closing recruitment when this quota 
is met. This method may also reduce the large variances in group sizes, leading to a more robust 
ANOVAs (Field, 2009). 
For a more accurate measure of participants’ PA, future research should use a self-report 
questionnaire that has been validated in a geriatric sample (Prince et al., 2008).  This used in 
conjunction with an objective measure of PA such an accelerometer or a measure of aerobic fitness 
may provide the most reliable results (Prince et al., 2008). Using a measure of life-time PA may also 
be beneficial to determine whether PA has long-term effects on cognitive functioning (Colcombe & 
Kramer, 2003).   
Dose-dependency suggests that being an APOE-4 homozygous carrier significantly 
increases risk of developing dementia than APOE-4 heterozygous carriers (Obiseasan et al., 2012). 
The current study did not have a large enough sample to warrant breaking down genotype groups 
from APOE-4 carriers and non-carriers to their specific genotypes (e.g. 4/4). Therefore, future 
research may benefit from further exploring the differences between homozygous APOE-4 carriers 
and heterozygous carriers. Literature has also suggested that the APOE-2 allele’s protective effects 
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against dementia and age-associated cognitive decline may overpower the risk factor APOE-4 
presents (Suri et al., 2013). Thus, future research may benefit by excluding 2/4 carriers from 
analysis to control for this affect.  
Future research should also aim to explore other variables that may interact with PA and 
APOE-4 on cognitive functioning. APOE is not the only gene associated with cognitive decline 
(Sapkota et al., 2015). It has been found that the combined effect of APOE and BDNF may lead to 
more pronounced effects on cognition (Sapkota et al., 2015; Ward et al., 2014). Therefore, future 
research may benefit from examining the gene environment interaction between APOE, BDNF, and 
PA. Other variables that may be important to consider include diet, social engagement, and education 
(Smith et al., 2010). 
Conclusions 
 Findings surrounding the potential effects of PA, APOE-4, and their interaction on age-
associated cognitive decline has been inconsistent and scarce. The research that has been conducted 
in this field has often comprised of small samples consisting of one gender (Etiner et al., 2007; 
Schuit et al., 2001), used unstandardized measures of PA that are not validated for geriatric samples 
(Podewils et al., 2005), and have relied on the use of the MMSE to determine cognitive functioning, 
ignoring potential domain-specific differences (Tombaugh & McLyntyre, 1992).  
 The current study aimed to overcome these limitations by examining the interaction of PA 
and APOE-4 across domains of cognitive functioning, assessing PA with a questionnaire valid for a 
geriatric sample, and accounted for social desirability bias via increasing MET cut-offs. Thus, though 
this study was not without limitation, it presented with some considerable strength over previous 
literature. Results of the current study revealed no significant effects or interactions between PA and 
APOE-4 on age-associated cognitive decline across the domains of EF, LTM, learning, and WM, 
contrary to the hypotheses. From the current research, genetically at risk groups cannot be identified, 
and groups that may benefit most from interventions also cannot be identified.  
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The findings of the current study suggest that PA and APOE-4 may not effect on age-
associated cognitive decline, and this effect may only be present in pathological cases. However, this 
is not consistent with all literature, thus future research is required. This research would benefit from 
employing a longitudinal design or a pre-test post-test PA intervention. Further, a large and 
representative sample, an objective measure of PA would help to determine whether this is a 
prevailing pattern of results, or due to methodological inconsistencies. Further, future research 
should examine possible relationships with other variables, such as diet, BDNF, and age, as well as 
investigating dose-dependency further. 
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Appendix A: Ethical Approval 
 
 
 
 
 
 
 
 
 
 
 
 
31 July 2017 
 
 
Ms Christine Padgett 
C/- University of Tasmania 
 
 
Sent via email 
 
 
 Dear Ms Padgett 
 
 
 
 
 
 
Document    Version    Date     
Low risk Application  13 July 2017 
HLAQ Modified for Australia  
 
Introduction for THBP Newsletter  
 
Cover letter Padgett   10 July 2017 
Email and Mail introduction PA and Gene Study  
 
Finance and Administration   
 
Incidental and Planned Exercise Questionnaire  
 
PICF PA   13 July 2017 
 
The Tasmanian Health and Medical Human Research Ethics Committee considered and 
approved the above documentation on 27 July 2017 to be conducted at the following 
site(s): 
 
Wicking Dementia Research and Education Centre 
 
Please ensure that all investigators involved with this project have cited the approved 
versions of the documents listed within this letter and use only these versions in 
conducting this research project. 
 
This approval constitutes ethical clearance by the Health and Medical HREC.  The 
decision and authority to commence the associated research may be dependent on 
factors beyond the remit of the ethics review process. For example, your research may 
need ethics clearance from other organisations or review by your research governance 
coordinator or Head of Department.  It is your responsibility to find out if the approvals of 
other bodies or authorities are required. It is recommended that the proposed research 
should not commence until you have satisfied these requirements. 
 
REF NO: H0016623 
TITLE:  Exploring the Roles of Physical Activity and Genetic Predictors on 
Cognition in Older Adults 
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All committees operating under the Human Research Ethics Committee (Tasmania) 
Network are registered and required to comply with the National Statement on the Ethical 
Conduct in Human Research (NHMRC 2007 updated 2014).  
Therefore, the Chief Investigator’s responsibility is to ensure that: 
(1) The individual researcher’s protocol complies with the HREC approved 
protocol. 
(2) Modifications to the protocol do not proceed until approval is obtained in writing 
from the HREC.  Please note that all requests for changes to approved documents must 
include a version number and date when submitted for review by the HREC. 
(3) Section 5.5.3 of the National Statement states: 
Researchers have a significant responsibility in monitoring approved research 
as they are in the best position to observe any adverse events or unexpected 
outcomes.  They should report such events or outcomes promptly to the 
relevant institution/s and ethical review body/ies and take prompt steps to deal 
with any unexpected risks. 
The appropriate forms for reporting such events in relation to clinical and non-clinical 
trials and innovations can be located at the website below. All adverse events must be 
reported regardless of whether or not the event, in your opinion, is a direct effect of the 
therapeutic goods being tested. http://www.utas.edu.au/research-admin/research-
integrity-and-ethics-unit-rieu/human-ethics/human-research-ethics-review-
process/health-and-medical-hrec/managing-your-approved-project 
 
(4) All research participants must be provided with the current Patient Information Sheet 
and Consent Form, unless otherwise approved by the Committee. 
(5) The Committee is notified if any investigators are added to, or cease 
involvement with, the project. 
(6) This study has approval for four years contingent upon annual review.  A 
Progress Report is to be provided on the anniversary date of your approval. 
Your first report is due 27 July 2018. You will be sent a courtesy reminder closer 
to this due date. 
(7) A Final Report and a copy of the published material, either in full or 
abstract, must be provided at the end of the project. 
 
Should you have any queries please do not hesitate to contact me on (03) 6226 6254. 
 
 
 
Yours sincerely 
Jude Vienna-Hallam 
Ethics Administration Officer  
 
 
 
 
 
 
50 
 
  
 
Appendix B: Participant Information Sheet 
 
 
 
PARTICIPANT INFORMATION SHEET 
Exploring the Roles of Physical Activity and Genetic Predictors on 
Cognition in Older Adults 
Invitation 
We would like to invite you to participate in a research project investigating whether physical 
activity influences the way genes might impact cognitive function (for example memory and 
learning).  This study is being run as a side-project by researchers in the Tasmanian Healthy Brain 
Project and researchers at the School of Medicine (Psychology). 
The study is being conducted by: 
• Dr Christine Padgett, Lecturer in the School of Medicine (Psychology), UTAS 
• Associate Professor Mathew Summers, Associate Professor of Neuropsychology and Mental 
Health, Thompson Institute, USC and Investigator in the Tasmanian Healthy Brain Project, 
UTAS 
• Professor James Vickers, Professor of Pathology, Wicking Centre, UTAS 
• Kimberley Stuart, Research Fellow and Project Co-ordinator, The Tasmanian Healthy Brain 
Project UTAS 
• Ruby Marris-Smith, 4th year Honours Student in the School of Medicine (Psychology) UTAS 
• Melissa Heather, 4th year Honours Student in the School of Medicine (Psychology) UTAS 
 
1. “What is the purpose of this study?” 
There is evidence that some genes might influence cognitive function in later life (for example, 
memory and learning).  However, it is possible that physical activity influences the effect of 
these genes.  Therefore we would like to investigate the relationship between physical activity, 
genes thought to influence cognition, and cognition in older adults. 
 
2. “Why have I been invited to participate in this study?” 
You have been invited to participate in this study because you are currently participating in the 
Tasmanian Healthy Brain Project. 
 
3. “What does this study involve?” 
For this study, you would be asked to complete two short questionnaires; one asking you about 
past levels of physical activity and the other asking about your current levels of physical activity.  
These questionnaires can be either completed online or can be mailed to your home, where you 
can complete and the return in a postage-paid envelope that we will provide.  Completing the 
questionnaires should only take about 10 minutes in total. 
We would also ask that we could access the results of the cognitive assessments you have 
undertaken as part of the Tasmanian Healthy Brain Project, as well as the genetic results from the 
samples you provided. It is important to note that any data provided by researchers at the 
Tasmanian Healthy Brain Project would not have your name or any information that could 
identify who you are.  Only Associate Professor Summers or Ms Stuart, who are also researchers 
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on the Tasmanian Healthy Brain Project, would have your identifying information, and would 
remove these details and insert an alpha-numeric code in its place before passing on as to the 
current project. 
 
4. “Are there any possible benefits from participating in this study?” 
It is not expected that there will be any specific benefits from participating in this study. 
 
5. “Are there any possible risks from participation in this study?” 
We do not foresee any risks associated with participating in this study. 
 
6. “What if I have questions about this research?” 
If you would like to discuss anything about this study you are very welcome to contact Dr 
Christine Padgett on 6430 4946 or email her at Christine.Padgett@utas.edu.au.  If you have 
concerns or complaints about the conduct of this study should contact the Executive Officer of 
the HREC (Tasmania) Network on (03) 6226 7479 or email human.ethics@utas.edu.au. The 
Executive Officer is the person nominated to receive complaints from research participants. You 
will need to quote HREC project number H0016623 
 
Thank you for taking the time to consider this study.  If you would like to take part, and have 
received this via email, please click on the link in this email.  This will take you to a consent 
form and then on to the survey.  If you have received this via mail, please complete the enclosed 
consent form and enclosed questionnaires and return using the postage paid envelope. 
This information sheet is for you to keep 
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Appendix C: Participant Consent Form: 
 
 
 
 
CONSENT FORM 
Exploring the Roles of Physical Activity and Genetic Predictors on Cognition in Older Adults 
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1. I have read and understood the information sheet for this project. 
 
2. I understand that I will be asked questions relating to past and present physical 
activity, and that this survey will take approximately 10-15 minutes to complete. 
 
3. I consent that the Tasmanian Healthy Brain Project can release my data to be included 
in this study. 
 
4. I understand that there are no foreseen risks associated with this study. 
 
5. I understand that all research data will be securely stored at the University of 
Tasmania for at least five years following publication of results, and will be destroyed 
when no longer required. 
 
6. Any questions that I have asked have been answered to my satisfaction. 
 
7. I agree that research data gathered from me for the study may be published provided 
that I cannot be identified as a participant. 
 
8. I understand that any information I provide will be only used for the purposes of this 
research. 
 
9. I understand that I may withdraw at any time without any consequences, and that I 
can request for my data to be removed from the study at any time. 
 
 
If you have read and understood the information sheet and above points, and wish to 
be involved in the study, please click ‘yes’ below and you will be directed to the 
survey.  If you do not wish to be part of this study, please click on the ‘No’ below and 
you will be exited from the survey.  We thank you for your time. 
 
Name of Participant:_________________________________________________________ 
 
Signature:_______________________________           
Date:_________________________ 
 
 
 
 
 
 
 
 
 
 
